DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation

The use of sialidase therapy for respiratory viral infections

(2013) John M. Nicholls et al.   ANTIVIRAL RESEARCH

The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation

(2012) R. F. Chemaly et al.   BLOOD

A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection

(2012) R. B. Moss et al.   JOURNAL OF INFECTIOUS DISEASES

DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient

(2012) D.R. Drozd et al.   Transplant Infectious Disease

Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients

(2012) B.B. Guzmán-Suarez et al.   Transplant Infectious Disease

Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation

(2011) Y.-B. Chen et al.   CLINICAL INFECTIOUS DISEASES

End Points for Testing Influenza Antiviral Treatments for Patients at High Risk of Severe and Life‐Threatening Disease

(2010) Michael G. Ison et al.   JOURNAL OF INFECTIOUS DISEASES

A Recombinant Sialidase Fusion Protein Effectively Inhibits Human Parainfluenza Viral Infection In Vitro and In Vivo

(2010) Anne Moscona et al.   JOURNAL OF INFECTIOUS DISEASES